C4 Therapeutics
CCCC
100 hedge funds and large institutions have $94.1M invested in C4 Therapeutics in 2023 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 36 increasing their positions, 35 reducing their positions, and 36 closing their positions.
2,467% more call options, than puts
Call options by funds: $154K | Put options by funds: $6K
3% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 35
6.45% less ownership
Funds ownership: 76.21% → 69.76% (-6.5%)
17% less funds holding
Funds holding: 120 → 100 (-20)
20% less capital invested
Capital invested by funds: $117M → $94.1M (-$23.3M)
56% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 36
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$6.37M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$4.77M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$3.21M |
| 4 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$2.44M |
| 5 |
D.E. Shaw & Co
New York
|
+$1.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$19.5M |
| 2 |
BlackRock
New York
|
-$5.18M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.99M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$1.29M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$1.12M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SO
126
STRS Ohio
Columbus,
Ohio
| – | -$17K | -5,600 | Closed |
|
127
Legal & General Group
London,
United Kingdom
| – | -$17.6K | -5,591 | Closed |
|
|
AB
128
Amalgamated Bank
New York
| – | -$13K | -4,184 | Closed |
|
129
Amundi
Paris,
France
| – | -$9.19K | -3,023 | Closed |
|
|
AIP
130
Ameritas Investment Partners
Lincoln,
Nebraska
| – | -$9.3K | -2,962 | Closed |
|
|
TIM
131
Tortoise Investment Management
White Plains,
New York
| – | -$4.71K | -1,500 | Closed |
|
|
MLICM
132
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$3.48K | -1,107 | Closed |
|
|
FHA
133
First Horizon Advisors
Memphis,
Tennessee
| – | -$2.9K | -924 | Closed |
|
|
DFCM
134
Dark Forest Capital Management
San Juan,
Puerto Rico
| – | -$421 | -134 | Closed |
|
135
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$354 | +110 | +239% |
|
CCCC Hedge Fund Activity: Q2 2023 in Review
100 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in C4 Therapeutics (CCCC) for Q2 2023, worth a combined $94.1M — down 20% from $117M a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of CCCC and 16 opened new positions — a net loss of 20 holders — while 35 trimmed existing stakes and 36 added.
The largest buyer was Millennium Management, adding an estimated $6.37M. The largest seller was ArrowMark Colorado Holdings, cutting an estimated $19.5M.
- 100 institutional investors held C4 Therapeutics (CCCC) as of Q2 2023, down from 120 in Q1 2023.
- Funds reported $94.1M of C4 Therapeutics stock for Q2 2023, down 20% quarter-over-quarter.
- 16 funds opened new C4 Therapeutics positions in Q2 2023 and 36 closed out, a net change of -20 holders.
- The largest C4 Therapeutics buyer in Q2 2023 was Millennium Management, an estimated $6.37M added.
- The largest C4 Therapeutics seller in Q2 2023 was ArrowMark Colorado Holdings, an estimated $19.5M sold.
Based on aggregated 13F filings for Q2 2023.